China SXT Pharmaceuticals
SXTC----
Q4 FY2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Overview: China SXT Pharmaceuticals(SXTC) the Revenue is 255.74 K (-43.88%);the EBIT is -392.01 K (+61.61%);the EPS is 0.14 (+100.2%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.00B43.88%
----
----
EBIT
-0.00B61.61%
----
----
EPS
0.1397100.18%
----
----
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf